Most promising are the three novel classes of mediations which have thus far been largely studied in adult patients: GLP1 receptor agonists, DPP4 inhibitors, and SGLT2 inhibitors, as well as dietary approaches to reverse diabetes and its associated complications (e.g., VLEDs). Here, DPP4 is linked to diabetes mellitus.